The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...

The French government has warned the United States investment company buying the consumer healthcare division of drugmaker Sanofi that it will incur penalties of more than 100 million euros ($107.6 ...

French drugmaker Sanofi's confirmation that it will sell a controlling stake in its consumer health unit to a US investment ...

French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit to a US ...

US private equity firm CD&R has agreed to French government demands seeking to protect jobs and investment in France. View on ...

PARIS (Reuters) -French drugmaker Sanofi said on Thursday it was "surprised" by a renewed, higher offer for its consumer arm ...

The gift will be spread over 10 years and divided among Morehouse, Howard University College of Medicine and Meharry Medical ...

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry from politicians on all sides.